{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:50:57Z","timestamp":1781783457090,"version":"3.54.5"},"reference-count":42,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"unspecified","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031365","name":"Oslo universitetssykehus HF","doi-asserted-by":"publisher","award":["2022021"],"award-info":[{"award-number":["2022021"]}],"id":[{"id":"10.13039\/100031365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020948","name":"AstraZeneca M\u00f6lndal","doi-asserted-by":"publisher","award":["Free study drug"],"award-info":[{"award-number":["Free study drug"]}],"id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Therapy Research\/ KLINBEFORSK","award":["32929"],"award-info":[{"award-number":["32929"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,5,31]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Recent studies have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease in people at high cardiovascular risk, with or without type 2 diabetes. To date, all published studies have excluded kidney transplant recipients (KTRs). The Dapagliflozin Early After Kidney Transplantation (DEAK) study aims to prospectively evaluate the effects of the SGLT2 inhibitor dapagliflozin on kidney function, histopathology and metabolic outcomes among de novo KTRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analyses<\/jats:title>\n                    <jats:p>This nationwide, investigator-initiated, single-transplant-centre, randomised, placebo-controlled, prospective clinical trial with two parallel groups aims to enrol 330 de novo adult KTRs (aged 18\u201375 years) with an estimated glomerular filtration rate (eGFR) of at least 25 mL\/min\/1.73 m\u00b2. Participants are enrolled 6\u20138\u2009weeks after transplantation and randomised 1:1 to receive dapagliflozin 10 mg\/day or placebo for 3 years. Recipients with conditions that may intermittently affect kidney function, such as recent acute rejection or ongoing infection, are ineligible for inclusion.<\/jats:p>\n                    <jats:p>The primary endpoint of the study is the difference in the chronic eGFR slope between treatment groups over 3 years, estimated using the European Kidney Function Consortium equation. Secondary and safety endpoints include changes in measured GFR (iohexol clearance), urinary albumin\/creatinine ratio, blood pressure, infections and safety clinical chemistry. Exploratory endpoints evaluated after 1.5 years include changes in body composition and glucose tolerance; between-group differences in urinary metabolomics; transplant kidney biopsy inflammation and fibrosis scores (n=140) and kidney biopsy messenger RNA and protein expression (n=50). The protocol also includes a 10-year poststudy registry follow-up of eGFR slope, cardiovascular events and graft and patient survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol (EudraCT number: 2022-002428-10) has been approved by the Norwegian Medical Products Agency, the Regional Committee for Medical Research Ethics in Southeast Norway (REK Southeast number 426076) and by the data protection offices at the participating hospitals. The main results will be published in international, peer-reviewed scientific journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05788276\">NCT05788276<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-117263","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:50:49Z","timestamp":1781779849000},"page":"e117263","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway\u2014the DEAK study"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct05788276","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05788276","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07143773","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0530-5263","authenticated-orcid":false,"given":"Ingrid Charlotte","family":"Kongerud","sequence":"first","affiliation":[{"name":"Department of Transplant Medicine, Oslo University Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Midtvedt","sequence":"additional","affiliation":[{"name":"Department of Transplant Medicine, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit D","family":"Solbu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital of North Norway, Troms\u00f8, Norway"},{"name":"Department of Clinical Medicine, The Artic University of Norway, Metabolic and Renal Research Group, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius A","family":"\u00d8vrehus","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway"},{"name":"Department of Nephrology, St Olav\u2019s Hospital HF, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Eikrem","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"Department of Nephrology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivar A","family":"Eide","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Nephrology, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Heldal","sequence":"additional","affiliation":[{"name":"Department of Transplant Medicine, Oslo University Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e5re","family":"Birkeland","sequence":"additional","affiliation":[{"name":"Department of Transplant Medicine, Oslo University Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00c5sberg","sequence":"additional","affiliation":[{"name":"Department of Transplant Medicine, Oslo University Hospital, Oslo, Norway"},{"name":"Department of Pharmacy, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-8274","authenticated-orcid":false,"given":"Trond G","family":"Jenssen","sequence":"additional","affiliation":[{"name":"Department of Transplant Medicine, Oslo University Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"2026061803502362000_16.6.e117263.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03686.x"},{"key":"2026061803502362000_16.6.e117263.2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001307","article-title":"A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments","volume":"9","author":"Wyld","year":"2012","journal-title":"PLoS Med"},{"key":"2026061803502362000_16.6.e117263.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02519.x"},{"key":"2026061803502362000_16.6.e117263.4","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14694"},{"key":"2026061803502362000_16.6.e117263.5","unstructured":"\u00c5sberg A . Annual report 2023. The Norwegian Renal Registry; 2023. Available: https:\/\/www.nephro.no\/registry.html"},{"key":"2026061803502362000_16.6.e117263.6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41574-018-0137-7","article-title":"Post-transplant diabetes mellitus in patients with solid organ transplants","volume":"15","author":"Jenssen","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"2026061803502362000_16.6.e117263.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.01749.x"},{"key":"2026061803502362000_16.6.e117263.8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000116"},{"key":"2026061803502362000_16.6.e117263.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2105-9"},{"key":"2026061803502362000_16.6.e117263.10","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020050566"},{"key":"2026061803502362000_16.6.e117263.11","first-page":"S17","article-title":"Vascular calcification in end-stage renal disease","volume":"17 Suppl 1","author":"Jablonski","year":"2013","journal-title":"Hemodial Int"},{"key":"2026061803502362000_16.6.e117263.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00573.x"},{"key":"2026061803502362000_16.6.e117263.13","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.15070920"},{"key":"2026061803502362000_16.6.e117263.14","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpae092"},{"key":"2026061803502362000_16.6.e117263.15","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04800908"},{"key":"2026061803502362000_16.6.e117263.16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ekir.2019.11.012","article-title":"Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance","volume":"5","author":"\u00c5sberg","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2026061803502362000_16.6.e117263.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02159.x"},{"key":"2026061803502362000_16.6.e117263.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12917-025-04748-2","article-title":"Volumetric absorptive microsampling to measure iohexol and creatinine concentrations for estimation of glomerular filtration rate in cats: aligning animal welfare with practical feasibility","volume":"21","author":"De Baets","year":"2025","journal-title":"BMC Vet Res"},{"key":"2026061803502362000_16.6.e117263.19","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/ndt\/gfx323","article-title":"Iohexol plasma clearance simplified by dried blood spot testing","volume":"33","author":"Luis-Lima","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2026061803502362000_16.6.e117263.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203769"},{"key":"2026061803502362000_16.6.e117263.21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.jrn.2017.09.001","article-title":"Development of Kidney Transplant Fibrosis Is Inversely Associated With Plasma Marine Fatty Acid Level","volume":"28","author":"Eide","year":"2018","journal-title":"J Ren Nutr"},{"key":"2026061803502362000_16.6.e117263.22","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.9.1440"},{"key":"2026061803502362000_16.6.e117263.23","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.9.1462"},{"key":"2026061803502362000_16.6.e117263.24","doi-asserted-by":"crossref","first-page":"E1727","DOI":"10.1210\/jc.2014-2059","article-title":"Dual-energy X-ray absorptiometry is a valid method to estimate visceral adipose tissue in adult patients with Prader-Willi syndrome during treatment with growth hormone","volume":"99","author":"Olarescu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061803502362000_16.6.e117263.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-025-04007-4","article-title":"Norwegian kidney biopsy biobank (NorKiBB): organization, baseline characteristics, and generalizability of a low-cost national biobank","volume":"26","author":"\u00d8vrehus","year":"2025","journal-title":"BMC Nephrol"},{"key":"2026061803502362000_16.6.e117263.26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","article-title":"Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Heerspink","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061803502362000_16.6.e117263.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"2026061803502362000_16.6.e117263.28","doi-asserted-by":"crossref","first-page":"F969","DOI":"10.1152\/ajprenal.00551.2017","article-title":"SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism","volume":"314","author":"Layton","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026061803502362000_16.6.e117263.29","unstructured":"Neuen BL , Fletcher RA , Anker SD , et al . SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis. JAMA 2025."},{"key":"2026061803502362000_16.6.e117263.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.02010.x"},{"key":"2026061803502362000_16.6.e117263.31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2018.05.015","article-title":"Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial","volume":"73","author":"Weiner","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2026061803502362000_16.6.e117263.32","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12850"},{"key":"2026061803502362000_16.6.e117263.33","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-1085"},{"key":"2026061803502362000_16.6.e117263.34","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.ekir.2024.05.022","article-title":"Cardioprotective Effect of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients: A Multicenter Propensity Score Matched Study","volume":"9","author":"Lim","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026061803502362000_16.6.e117263.35","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15223"},{"key":"2026061803502362000_16.6.e117263.36","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","article-title":"The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients","volume":"106","author":"Lim","year":"2022","journal-title":"Transplantation"},{"key":"2026061803502362000_16.6.e117263.37","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/ckj\/sfad007","article-title":"Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study","volume":"16","author":"S\u00e1nchez Fructuoso","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026061803502362000_16.6.e117263.38","unstructured":"SGLT2i safety and efficacy on kidney allograft function in non-diabetic kidney transplant recipients: a randomized, double-blind, placebo controlled, national, multicenter trial. 2025. Available: https:\/\/clinicaltrials.gov\/study\/NCT07143773"},{"key":"2026061803502362000_16.6.e117263.39","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/ndt\/gfaf046","article-title":"Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease","volume":"40","author":"Bakker","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026061803502362000_16.6.e117263.40","article-title":"ACE Inhibitors and ARBs in Chronic Kidney Disease: A Systematic Review of Randomized Controlled Trials on Albuminuria Reduction, eGFR Decline, and Safety","volume":"17","author":"Avula","year":"2025","journal-title":"Cureus"},{"key":"2026061803502362000_16.6.e117263.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2009.00922.x"},{"key":"2026061803502362000_16.6.e117263.42","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200112150-00013"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-117263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:50:55Z","timestamp":1781779855000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-117263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,18]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/bmjopen-2026-117263"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-117263","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}